MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.transproceed.2019.01.106

Медицинская библиотека · Transplantation proceedings · 2019

Effects of Rituximab on Atherosclerotic Biomarkers in Kidney Transplant Recipients.

Aliyeva N, Demir E, Akgul S U, Temurhan S, Ucar A R, Dirim A B, Bayraktar A, Catikkas N M, Erol A, Caliskan Y, Yazici H, Yelken B, Savran F O, Turkmen A

СтатьяПеревод в очереди

Аннотация

INTRODUCTION

Cardiovascular disease is the leading cause of mortality in kidney transplant recipients. Rituximab is widely used in kidney transplantation for a variety of situations, and rituximab may inhibit some cytokines and antibodies that may play an active role in the atherosclerotic process. The aim of the study was to evaluate the efficacy of rituximab on atherosclerosis biomarkers in kidney transplant recipients.

METHODS

All patients, 18 years of age and older, who underwent kidney transplantation and received at least 1 dose of 375 mg/m2 rituximab were considered for participation in this study. The primary study endpoint was the development of cardiovascular diseases after rituximab therapy. The secondary endpoint was the onset of cytomegalovirus (CMV) disease or biopsy-confirmed BK virus nephropathy. In addition, comparison of atherosclerosis biomarkers was performed between study and control groups.

RESULTS

There were no cardiovascular events observed during follow up. Only 8 patients in the study group suffered from CMV disease during follow up. Serum interleukin 10 levels were significantly higher in the rituximab group compared with the control group, although anti-oxidized low-density lipoprotein levels were lower in the rituximab group compared with the control group, though this did not achieve statistical significance.

DISCUSSION: Rituximab treatment may increase the risk of CMV reactivation and decrease lymphocyte counts and interleukin 10 levels; however, significant decreases in all atherosclerotic-related biomarkers have not been shown in our study.

Для цитирования: Aliyeva N, Demir E, Akgul S U, Temurhan S, Ucar A R, Dirim A B, Bayraktar A, Catikkas N M, Erol A, Caliskan Y, Yazici H, Yelken B, Savran F O, Turkmen A. Effects of Rituximab on Atherosclerotic Biomarkers in Kidney Transplant Recipients.. Transplantation proceedings. 2019. DOI: 10.1016/j.transproceed.2019.01.106.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.